# US 2015/0147274 A1 · Antibodies against hgf - receptor and uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147274 A1
- Document ID: US20150147274A1
- Status: Published application
- Kind: A1
- Application number: 14/362,221
- Filed: 2012-11-30
- Published: 2015-05-28
- Earliest claimed: 2011-12-02
- Assignees: Cancer Research Technology Limited
- Applicants: Cancer Research Technology Limited
- Inventors: Danielle Marie Di Cara; John McCafferty; Ermanno Gherardi; Anthony Richard Pope
- Web page: https://patentgrep.com/patent/US20150147274A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 49/0004: {Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions}
- A61P 35/00: Antineoplastic agents
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.

## Claims

### Claim 1

An antibody that specifically binds to the extracellular domain of the human HGF receptor (MET) (SEQ ID No: 1), wherein the antibody comprises:
a heavy chain CDR1 comprising the amino acid sequence DYYMH (SEQ ID NO:2), or a variant thereof comprising 1, 2 or 3 amino acid substitutions,
a heavy chain CDR2 comprising the amino acid sequence LVDPEDGETIYAEKFQ (SEQ ID NO:3), or a variant thereof comprising 1, 2 or 3 amino acid substitutions,
a heavy chain CDR3 comprising the amino acid sequence DATTPYYGMDV (SEQ ID NO:4), or a variant thereof wherein
the Y at position 7 is replaced with W,
the G at position 8 is replaced with F,
the M at position 9 is replaced with P,
the D at position 10 is replaced with M, W, V, Q, R or Y, and/or
the V at position 11 is replaced with E, W, Q, S, T, L, E or L, or a combination thereof,
a light chain CDR1 comprising the amino acid sequence QASQDISNYLN (SEQ ID NO:13), or a variant thereof comprising 1, 2 or 3 amino acid substitutions,
a light chain CDR2 comprising the amino acid sequence DASNLET (SEQ ID NO:14), or a variant thereof comprising 1, 2 or 3 amino acid substitutions, and
a light chain CDR3 comprising the amino acid sequence QQGDSFPLT (SEQ ID NO:15), or a variant thereof comprising 1, 2 or 3 amino acid substitutions.

### Claim at position 2

2-11. (canceled)

### Claim 12 (depends on 1)

The antibody according to claim 1, wherein the amino acid substitutions are conservative amino acid substitutions.

### Claim 13 (depends on 1)

The antibody according to claim 1, wherein the antibody comprises the amino acid sequence of SEQ ID NO: 26, or wherein the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 28 and a light chain amino acid sequence of SEQ ID NO: 29, or wherein the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 30 and a light chain amino acid sequence of SEQ ID NO: 31, or wherein the antibody comprises a heavy chain amino acid sequence of SEQ ID NO: 32 and a light chain amino acid sequence of SEQ ID NO: 31.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

An The antibody according to claim 1, wherein the antibody specifically binds to amino acid residues 568-741 of human MET (SEQ ID No: 1).

### Claim 16 (depends on 1)

The antibody according to claim 1, wherein the antibody binds to the extracellular of the human MET with an affinity of at least 1 nM, and preferably with an affinity of at least 0.5 nM.

### Claim at position 8

17-22. (canceled)

### Claim 23

An antibody that specifically binds to an epitope located within amino acid residues 592-615 of human MET (SEQ ID No: 1).

### Claim at position 10

24-34. (canceled)

### Claim 35 (depends on 1)

The antibody according to claim 1, wherein the antibody is an antigen-binding fragment of an antibody; or a domain antibody.

### Claim 36 (depends on 35)

The antibody according to claim 35 wherein the antigen-binding fragment is an Fv fragment.

### Claim 37 (depends on 35)

The antibody according to claim 35 wherein the antigen-binding fragment is a Fab-like fragment.

### Claim 38 (depends on 1)

The antibody according to claim 1, wherein the antibody is a monovalent antibody.

### Claim 39 (depends on 1)

The antibody according to claim 1, wherein the antibody is a monoclonal antibody.

### Claim 40 (depends on 1)

The antibody according to claim 1, wherein the antibody is human or humanised.

### Claim 41 (depends on 1)

The antibody according to claim 1, wherein the antibody is a recombinant antibody.

### Claim 42 (depends on 1)

The antibody according to claim 1, wherein the antibody is in an isolated and/or purified form.

### Claim 43 (depends on 1)

The antibody according to claim 1, wherein the antibody has been PEGylated.

### Claim 44 (depends on 1)

A nucleic acid molecule encoding the antibody of claim 1.

### Claim 45 (depends on 44)

A vector comprising the nucleic acid of claim 44.

### Claim 46 (depends on 45)

A host cell comprising the vector of claim 45.

### Claim 47 (depends on 1)

A compound comprising an antibody according to claim 1 and a detectable moiety.

### Claim 48 (depends on 47)

The compound according to claim 47 wherein the detectable moiety comprises an enzyme, a radioactive atom, a fluorescent moiety, a chemiluminescent moiety or a bioluminescent moiety.

### Claim 49 (depends on 47)

The compound according to claim 47 wherein the antibody is an scFv fragment.

### Claim 50 (depends on 1)

A compound comprising an antibody according to claim 1 and a cytotoxic moiety.

### Claim at position 27

51-52. (canceled)

### Claim 53 (depends on 50)

The compound according to claim 50 wherein the antibody is an Fab fragment.

### Claim 54 (depends on 1)

A pharmaceutical composition comprising the antibody according to claim 1, and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 55 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising at least one additional anti-cancer agent.

### Claim 56 (depends on 1)

A kit of parts comprising the antibody according to claim 1 and at least one additional anti-cancer agent.

### Claim at position 32

57-58. (canceled)

### Claim 59 (depends on 1)

A method of inhibiting activity of human MET on a cell, of inhibiting human MET-mediated cellular proliferation, or of inhibiting human MET-mediated cellular migration, the method comprising contacting the cell with an effective amount of the antibody according to claim 1.

### Claim 60 (depends on 59)

The method of claim 59 wherein the cell is a tumour cell.

### Claim 61

(canceled)

### Claim 62 (depends on 59)

The method of claim 59 which is performed on cells in vivo.

### Claim 63 (depends on 1)

A method of inhibiting growth and/or metastasis of a tumour in a human patient, the method comprising administering to the patient a therapeutically effective amount of the antibody according to claim 1.

### Claim 64 (depends on 1)

A method of treating cancer in a human patient, the method comprising administering to the patient a therapeutically effective amount of the antibody according to claim 1.

### Claim at position 39

65-70. (canceled)

### Claim 71 (depends on 60)

The method claim 60 wherein the tumour or cancer is breast cancer, pancreatic cancer, colon cancer, gastric cancer or lung cancer.

### Claim 72

(canceled)

### Claim 73 (depends on 47)

A method of detecting the presence of human MET on a cell, the method comprising contacting the cell with a compound according to claim 47 and detecting the detectable moiety.

### Claim 74 (depends on 73)

The method of claim 73 wherein the cell is a tumour or cancer cell.

### Claim 75

(canceled)

### Claim 76 (depends on 73)

The method of claim 73 which is performed on cells in vivo.

### Claim at position 46

77-78. (canceled)

### Claim 79 (depends on 74)

The method according to claim 74, wherein the tumour or cancer is selected from bladder cancer, brain cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer including small cell and non-small-cell lung cancer, medulloblastoma, nasopharyngeal cancer, gastric cancer, oesophageal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, papillary renal cell carcinoma, prostate cancer, rhabdomyosarcoma, stomach cancer, thyroid cancer, cholangiocarcinoma, osteosarcoma, rhabdomyosarcoma, synovial sarcoma, Kaposi's sarcoma, leiomyosarcomas, fibrosarcoma, leukaemia including acute myelogenous leukaemia, adult T-cell leukaemia and chronic myeloid leukaemia, lymphoma, multiple myeloma, melanoma, mesothelioma, Wilms tumour, glioblastomata and astrocytoma.

### Claim at position 48

80-90. (canceled)

### Claim 91 (depends on 1)

A method of treating endometriosis, rheumatoid arthritis, or hypoglycaemia in a human patient, or for treating, reversing or minimising side-effects associated with the use of a Met-agonist in a human patient, the method comprising administering to the patient a therapeutically effective amount of the antibody according to claim 1.

### Claim at position 50

92-94. (canceled)

### Claim 95 (depends on 36)

The antibody according to claim 36 wherein the Fv fragment is a single chain Fv or a disulphide-bonded Fv.

### Claim 96 (depends on 37)

The antibody according to claim 37 wherein the Fab Fab-like fragment is an Fab fragment, an Fab′ fragment, or an F(ab)2 fragment.
